-lisib
A PI3K inhibitor, blocking phosphoinositide 3-kinase; used in some blood and breast cancers.
- Drugs ending in -lisib: 38
- Approved somewhere: 7
- With a US drug page: 8
- Stem
- -lisib
- Class
- Drugs that block PI3 kinase, mostly for cancer
Approved and clinical-stage drugs in ChEMBL whose names ending in -lisib, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Alpelisib | Approved | PIK3CA | PI3-kinase p110-alpha subunit inhibitor |
| Copanlisib | Approved | PIK3CA, PIK3CD | PI3-kinase p110-alpha subunit inhibitor |
| Duvelisib | Approved | PIK3CD, PIK3CG | PI3-kinase p110-delta subunit inhibitor |
| Idelalisib | Approved | PIK3CD | PI3-kinase p110-delta subunit inhibitor |
| Inavolisib | Approved | PIK3CA | PI3-kinase p110-alpha subunit inhibitor |
| Leniolisib | Approved | PIK3CD | PI3-kinase p110-delta subunit inhibitor |
| Umbralisib | Approved | PIK3CD, CSNK1E, ABL1 | PI3-kinase p110-delta subunit inhibitor |
| Gedatolisib | Phase 3 | MTOR, PI3-kinase class I | Serine/threonine-protein kinase mTOR inhibitor |
| Buparlisib | Phase 3 | PI3-kinase class I | PI3-kinase class I inhibitor |
| Dactolisib | Phase 3 | MTOR, PI3-kinase class I | Serine/threonine-protein kinase mTOR inhibitor |
| Parsaclisib | Phase 3 | PIK3CD | PI3-kinase p110-delta subunit inhibitor |
| Taselisib | Phase 3 | PI3-kinase class I | PI3-kinase class I inhibitor |
| Zandelisib | Phase 3 | PIK3CD | PI3-kinase p110-delta subunit inhibitor |
| Amdizalisib | Phase 2 | — | — |
| Apitolisib | Phase 2 | MTOR, PI3-kinase class I | Serine/threonine-protein kinase mTOR inhibitor |
| Bimiralisib | Phase 2 | — | — |
| Bosmolisib | Phase 2 | — | — |
| Gilmelisib | Phase 2 | — | — |
| Izorlisib | Phase 2 | PI3-kinase class I | PI3-kinase class I inhibitor |
| Linperlisib | Phase 2 | — | — |
| Nemiralisib | Phase 2 | PIK3CD | PI3-kinase p110-delta subunit inhibitor |
| Paxalisib | Phase 2 | PI3-kinase class I | PI3-kinase class I inhibitor |
| Pictilisib | Phase 2 | PI3-kinase class I | PI3-kinase class I inhibitor |
| Pilaralisib | Phase 2 | PI3-kinase class I | PI3-kinase class I inhibitor |
| Risovalisib | Phase 2 | — | — |
| Roginolisib | Phase 2 | — | — |
| Samotolisib | Phase 2 | MTOR, PI3-kinase class I | Serine/threonine-protein kinase mTOR inhibitor |
| Seletalisib | Phase 2 | PIK3CD | PI3-kinase p110-delta subunit inhibitor |
| Serabelisib | Phase 2 | PIK3CA | PI3-kinase p110-alpha subunit inhibitor |
| Sonolisib | Phase 2 | PI3-kinase class I | PI3-kinase class I inhibitor |
| Tenalisib | Phase 2 | PIK3CD, PIK3CG | PI3-kinase p110-delta subunit inhibitor |
| Voxtalisib | Phase 2 | MTOR, PI3-kinase class I | Serine/threonine-protein kinase mTOR inhibitor |
| Vulolisib | Phase 2 | — | — |
| Acalisib | Phase 1 | PIK3CD | PI3-kinase p110-delta subunit inhibitor |
| Eganelisib | Phase 1 | PIK3CG | PI3-kinase p110-gamma subunit inhibitor |
| Omipalisib | Phase 1 | PI3-kinase class I, MTOR | PI3-kinase class I inhibitor |
| Panulisib | Phase 1 | PI3-kinase class I, MTOR, ACVRL1 | PI3-kinase class I inhibitor |
| Recilisib | — | PI3-kinase class I | PI3-kinase class I inhibitor |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO